Layoff
May 2026After the ALS asset failed and the company rebranded as Verge Labs, reporting indicated Verge cut about 90% of its workforce and pivoted to a leaner platform-first model.
SourceWe use human data and AI to develop better drugs faster.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Verge Genomics, now publicly operating as Verge Labs, is a 2015-founded San Francisco biotech/AI company focused on precision neurology and AI-driven drug discovery using its proprietary CONVERGE platform and multimodal human brain data.
Primary product
CONVERGE® all-in-human drug discovery / precision neurology platform (including vBx-1.0)
Founded
2015
Headquarters
San Francisco, California, United States
Team size
10-20
Work style
Flexible
Industry
Biotechnology Research
Sub-industry
AI-driven drug discovery and precision neurology
Offices